To compare conventional ultrasonography (US) and magnetic resonance (MR) imaging with contrast agent-enhanced US for detection of VX-2 liver tumors in rabbits.
Conventional gray-scale liver US was ...performed in 65 rabbits, 38 of which had VX-2 hepatic tumor implants. Twenty minutes after contrast agent injection, gray-scale pulse-inversion harmonic US images of the liver-specific phase were obtained. Following sacrifice of the animals, T1- and T2-weighted MR imaging was performed at 4-mm intervals. Pathologic analysis was performed as the reference standard. The capability of each imaging modality to correctly depict tumor presence or absence and the number of tumors was compared.
Conventional US correctly depicted the presence or absence of tumors in 54 rabbits, for an accuracy of 83%, sensitivity of 71%, and specificity of 100%. With contrast-enhanced US, accuracy increased to 92% (60 correct cases); sensitivity, to 87%; and specificity, to 100%. MR imaging facilitated 56 correct diagnoses, for an accuracy of 86%, sensitivity of 82%, and specificity of 93%. There was a marginally significant difference between US with and US without contrast agent (P =.07) but not between MR imaging and contrast-enhanced US (P > or = .34). When the numbers of correctly detected tumors were compared, contrast-enhanced US performed significantly better than MR imaging (P =.02) and conventional US (P =.04).
There was no significant difference between contrast-enhanced US and MR imaging in the detection of hepatic tumors, whereas contrast-enhanced US had the highest accuracy (92%) of the three modalities studied.
Benign and malignant breast tissue classification is examined for generalized-spectrum parameters computed from RF ultrasound data when a preclassification of subregions based on general scattering ...properties is performed. Results using a clinical database of 84 patients show statistically significant improvements (over 10% in receiver operation characteristic (ROC) areas) when only coherent scatterer subregions are used as compared to using all subregions within the region of interest.
Accurate detection and segmentation of suspicious regions within the complex and irregular tissues of the breast, as depicted with ultrasonic B scans, typically require human analysis and decision ...making. Tissue characterization methods for classifying suspicious regions often depend on identifying and then accurately segmenting these regions. Motivated by an ultimate goal to automate this critical identification and segmentation step for tissue characterization problems, this work examines ultrasonic signal characteristics between various regions of breast tissue broadly classified as normal tissue and breast lesions. This paper introduces a nonparametric model based on order statistics (OS) estimated from multiresolution (MR) decompositions of energy-normalized subregions. Experimental results demonstrate the classification performance of the OS-based features extracted from the tumor and normal tissue regions in multiple scans from 84 patients, which resulted in a total of 204 tumor regions (from 43 malignant and 161 benign) and 816 normal tissue regions. Performance results indicate that OS-based features achieved an area under the receiver-operator characteristic curve of 91% in the discrimination between breast lesions and surrounding normal tissues.
There is a strong interest in finding out which statistical model is the most appropriate for describing the envelope of the backscattered ultrasonic echoes from different types of tissues. The ...Rayleigh model is commonly employed, but this requires conditions, such as the presence of large number of randomly located scatterers with fairly uniform cross-sections, that are not always met. However, our research indicates that a model based on the K-distribution may provide a better fit to empirical data over a range of scattering conditions than the standard Rayleigh model. In this study, we looked at the K-distribution as a descriptor of the backscattered envelope of the breast and liver tissues (in vivo). By examining data from various tissue regions, a goodness-of-fit test (a least squares error method) was used to determine whether a Rayleigh or K-distribution model is more appropriate. From a large group of patients and volunteer scans (a total of 72 subjects), the fit between the K-distribution and the data is shown to have a much smaller error than the Rayleigh model.
To show that benign asymmetric breast tissue detected mammographically may increase over time.
Serial mammograms obtained in 21 women with negative physical examination results and mammographically ...detected developing asymmetric breast tissue were reviewed, and findings were correlated with results of biopsy (n = 16), ultrasonography (US) (n = 8), and contrast material-enhanced magnetic resonance (MR) imaging (n = 3). Five patients who did not undergo biopsy were followed up for 13-84 months. Thirteen of 16 biopsy specimens were reviewed.
At the time of mammographic change, 12 patients without baseline asymmetric tissue had a mean age of 41.7 years and a mean size of asymmetric tissue of 2.4 cm. The mean age of nine patients with baseline asymmetric tissue was 46.9 years. In eight patients, the mean size increase was 2.5 cm. One patient showed increased tissue density but stable size. All US and MR images were negative. Pseudoangiomatous stromal hyperplasia was present in all 13 biopsy specimens reviewed and extensive in 12. No malignancies have been reported in five of the followed-up patients, and two have had continued enlargement of asymmetric tissue.
Pseudoangiomatous stromal hyperplasia is a common histopathologic finding in developing asymmetric breast tissue. Follow-up, rather than biopsy, is a management option if benign imaging and clinical criteria are met.
Frequency compounding was recently investigated for computer aided classification of masses in ultrasonic B-mode images as benign or malignant. The classification was performed using the normalized ...parameters of the Nakagami distribution at a single region of interest at the site of the mass. A combination of normalized Nakagami parameters from two different images of a mass was undertaken to improve the performance of classification. Receiver operating characteristic (ROC) analysis showed that such an approach resulted in an area of 0.83 under the ROC curve. The aim of the work described in this paper is to see whether a feature describing the characteristic of the boundary can be extracted and combined with the Nakagami parameter to further improve the performance of classification. The combination of the features has been performed using a weighted summation. Results indicate a 10% improvement in specificity at a sensitivity of 96% after combining the information at the site and at the boundary. Moreover, the technique requires minimal clinical intervention and has a performance that reaches that of the trained radiologist. It is hence suggested that this technique may be utilized in practice to characterize breast masses.
There are two reasons for radiologic evaluation of the augmented breast. Because women with implants are at the same risk for breast cancer as other women, imaging is performed to screen for cancer ...or to work up clinical abnormalities. Additionally, imaging allows assessment of implant integrity. The various methods for imaging implants and breast tissue in the augmented patient are discussed. Imaging findings suggestive of silicone gel implant rupture are presented.
A novel variant of concern (VOC) named CAL.20C (B.1.427/B.1.429), which was originally detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C in the N-terminal ...domain (NTD), and L452R in the receptor-binding domain (RBD). Plasma from individuals vaccinated with a Wuhan-1 isolate-based messenger RNA vaccine or from convalescent individuals exhibited neutralizing titers that were reduced 2- to 3.5-fold against the B.1.427/B.1.429 variant relative to wild-type pseudoviruses. The L452R mutation reduced neutralizing activity in 14 of 34 RBD-specific monoclonal antibodies (mAbs). The S13I and W152C mutations resulted in total loss of neutralization for 10 of 10 NTD-specific mAbs because the NTD antigenic supersite was remodeled by a shift of the signal peptide cleavage site and the formation of a new disulfide bond, as revealed by mass spectrometry and structural studies.
Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat ...patients with inflammatory bowel diseases (IBD), but there are few data on its efficacy in patients with PSC. We investigated the effects of vedolizumab in a large international cohort of patients with PSC and IBD.
We collected data from European and North American centers participating in the International PSC Study Group from patients with PSC and IBD who received at least 3 doses of vedolizumab (n = 102; median vedolizumab treatment duration, 412 days). Demographic and clinical data were collected from baseline and during the follow-up period (until liver transplantation, death, or 56 days after the final vedolizumab infusion). We analyzed overall changes in biochemical features of liver and proportions of patients with reductions in serum levels of alkaline phosphatase (ALP) of 20% or more, from baseline through last follow-up evaluation. Other endpoints included response of IBD to treatment (improved, unchanged, or worsened, judged by the treating clinician, as well as endoscopic score) and liver-related outcomes.
In the entire cohort, the median serum level of ALP increased from 1.54-fold the upper limit of normal at baseline to 1.64-fold the upper limit of normal at the last follow-up examination (P = .018); serum levels of transaminases and bilirubin also increased by a small amount between baseline and the last follow-up examination. Serum levels of ALP decreased by 20% or more in 21 patients (20.6%); only the presence of cirrhosis (odds ratio, 4.48; P = .019) was independently associated with this outcome. Of patients with available endoscopic data, 56.8% had a response of IBD to treatment. Liver-related events occurred in 21 patients (20.6%), including bacterial cholangitis, cirrhosis decompensation, or transplantation.
In an analysis of patients with PSC and IBD in an international study group, we found no evidence for a biochemical response to vedolizumab, although serum level of ALP decreased by 20% or more in a subset of patients. Vedolizumab appears to be well tolerated and the overall response of IBD was the same as expected for patients without PSC.
Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-CoV-2 infection is crucial for understanding immune protection and identifying targets for vaccine design. ...In a cohort of 647 SARS-CoV-2-infected subjects, we found that both the magnitude of Ab responses to SARS-CoV-2 spike (S) and nucleoprotein and nAb titers correlate with clinical scores. The receptor-binding domain (RBD) is immunodominant and the target of 90% of the neutralizing activity present in SARS-CoV-2 immune sera. Whereas overall RBD-specific serum IgG titers waned with a half-life of 49 days, nAb titers and avidity increased over time for some individuals, consistent with affinity maturation. We structurally defined an RBD antigenic map and serologically quantified serum Abs specific for distinct RBD epitopes leading to the identification of two major receptor-binding motif antigenic sites. Our results explain the immunodominance of the receptor-binding motif and will guide the design of COVID-19 vaccines and therapeutics.
Display omitted
•SARS-CoV-2 RBD is immunodominant and accounts for 90% of serum neutralizing activity•RBD antibodies decline with a half-life of ∼50 days, but their avidity increases•Structural definition of a SARS-CoV-2 RBD antigenic map using monoclonal antibodies•ACE2-binding site dominates SARS-CoV-2 polyclonal neutralizing antibody responses
Serological analyses of ∼650 SARS-CoV-2-exposed individuals show that 90% of the serum or plasma neutralizing activity targets the virus receptor-binding domain, with structural insights revealing how distinct types of neutralizing antibodies targeting the ACE2-binding site dominate the immune response against SARS-CoV-2 spike.
PDF
